BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $344,640 | +2.9% | 48,678 | +2.4% | 0.00% | – |
Q2 2023 | $334,809 | -15.0% | 47,558 | +0.7% | 0.00% | – |
Q1 2023 | $393,690 | -26.8% | 47,205 | +0.8% | 0.00% | – |
Q4 2022 | $537,506 | -58.5% | 46,821 | -54.4% | 0.00% | -100.0% |
Q3 2022 | $1,294,000 | -38.7% | 102,666 | -48.5% | 0.00% | -50.0% |
Q2 2022 | $2,110,000 | +251.1% | 199,409 | +439.1% | 0.00% | – |
Q1 2022 | $601,000 | +12.5% | 36,992 | -3.9% | 0.00% | – |
Q4 2021 | $534,000 | -30.6% | 38,501 | -28.1% | 0.00% | -100.0% |
Q3 2021 | $769,000 | -21.6% | 53,513 | -13.8% | 0.00% | 0.0% |
Q2 2021 | $981,000 | +32.6% | 62,084 | -14.7% | 0.00% | 0.0% |
Q1 2021 | $740,000 | +32.9% | 72,741 | -2.7% | 0.00% | – |
Q4 2020 | $557,000 | +194.7% | 74,780 | +36.1% | 0.00% | – |
Q3 2020 | $189,000 | -30.0% | 54,964 | -3.1% | 0.00% | – |
Q2 2020 | $270,000 | +309.1% | 56,698 | +72.5% | 0.00% | – |
Q1 2020 | $66,000 | -39.4% | 32,874 | +4.5% | 0.00% | – |
Q4 2019 | $109,000 | +14.7% | 31,465 | -5.1% | 0.00% | – |
Q3 2019 | $95,000 | -15.9% | 33,144 | +11.4% | 0.00% | – |
Q2 2019 | $113,000 | -55.3% | 29,753 | -4.1% | 0.00% | – |
Q1 2019 | $253,000 | +3.7% | 31,037 | +2.8% | 0.00% | – |
Q4 2018 | $244,000 | +79.4% | 30,180 | +69.7% | 0.00% | – |
Q3 2018 | $136,000 | -18.1% | 17,780 | -38.6% | 0.00% | – |
Q2 2018 | $166,000 | +26.7% | 28,960 | +5.4% | 0.00% | – |
Q1 2018 | $131,000 | +5.6% | 27,478 | +9.1% | 0.00% | – |
Q4 2017 | $124,000 | +96.8% | 25,193 | +109.3% | 0.00% | – |
Q3 2017 | $63,000 | -21.2% | 12,039 | -16.3% | 0.00% | – |
Q2 2017 | $80,000 | -27.9% | 14,375 | +8.5% | 0.00% | – |
Q1 2017 | $111,000 | +32.1% | 13,250 | +0.3% | 0.00% | – |
Q4 2016 | $84,000 | +44.8% | 13,205 | 0.0% | 0.00% | – |
Q3 2016 | $58,000 | +61.1% | 13,205 | +4.5% | 0.00% | – |
Q2 2016 | $36,000 | 0.0% | 12,639 | 0.0% | 0.00% | – |
Q1 2016 | $36,000 | -71.7% | 12,639 | +2.6% | 0.00% | – |
Q4 2015 | $127,000 | -9.3% | 12,317 | 0.0% | 0.00% | – |
Q3 2015 | $140,000 | -6.7% | 12,317 | +22.3% | 0.00% | – |
Q2 2015 | $150,000 | +0.7% | 10,070 | -38.9% | 0.00% | – |
Q1 2015 | $149,000 | -36.6% | 16,477 | -14.9% | 0.00% | – |
Q4 2014 | $235,000 | +29.1% | 19,356 | +4.2% | 0.00% | – |
Q3 2014 | $182,000 | -12.5% | 18,567 | +13.9% | 0.00% | – |
Q2 2014 | $208,000 | – | 16,296 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |